rs2023239 — CNR1

Intronic variant near the CNR1 exon 3 alternative promoter that modulates CB1 receptor mRNA isoform balance; the C (risk) allele is associated with greater hippocampal volume loss in heavy cannabis users, heightened cannabis withdrawal and craving, and participation in a female-specific nicotine dependence haplotype

See your personal result for CNR1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Hippocampal Risk Variant — How a CNR1 Intronic SNP Shapes Cannabis Brain Vulnerability

Deep in intron 2 of the CNR1 gene — about 400 base pairs upstream from an alternative exon 3 transcription start site11 alternative exon 3 transcription start site
An alternative promoter within intron 2 of CNR1 that drives production of a novel CB1 receptor transcript with a different 5' untranslated region; this isoform shows regionally selective expression across brain areas including the hippocampus and prefrontal cortex — sits rs2023239, a T-to-C substitution that alters CB1 receptor isoform balance in ways that matter most for cannabis users. The C allele (reported as "G" in papers using coding-strand notation, because CNR1 is encoded on the minus strand of chromosome 6) is the minor allele globally at roughly 17–21% frequency, and it is the allele consistently associated with greater neurobiological sensitivity to cannabis.

CB1 is the most abundant G-protein-coupled receptor in the central nervous system. When THC — the primary psychoactive compound in cannabis — binds CB1, it floods the same signaling pathway activated by the brain's endogenous cannabinoids anandamide and 2-AG, releasing dopamine in the nucleus accumbens22 nucleus accumbens
The brain's primary reward hub; dopamine release here encodes the rewarding value of experiences and substances, and repeated activation by THC progressively recalibrates reward set-points toward dependence, suppressing glutamate and GABA release across the cortex, amygdala, hippocampus, and cerebellum. Genetic variation in CNR1 shapes how powerfully this cascade operates — and rs2023239 sits at a regulatory junction that influences which CB1 transcript variants the brain produces and in what quantity.

The Mechanism

Rs2023239 lies adjacent to a secondary promoter in CNR1 intron 2 that initiates transcription of a distinct CB1 receptor mRNA with an alternative 5' untranslated region (5'UTR). This alternative transcript shows regionally selective expression in brain33 regionally selective expression in brain
Not all CB1 transcripts are expressed equally everywhere; this secondary-promoter isoform is particularly expressed in brain regions with dense CB1 signaling, including the hippocampus, amygdala, and prefrontal cortex — the exact circuits involved in memory, emotion, and reward. The alternative 5'UTR differs from the canonical transcript in its regulatory binding sequences, affecting mRNA stability, translation efficiency, and potentially microRNA targeting.

Unlike rs806368 (CNR1's 3'UTR regulatory variant, which is a validated eQTL across three brain regions) and rs1049353 (the exon-synonymous variant near an exon splice enhancer), rs2023239 does not have a confirmed eQTL relationship yet established in large brain expression databases. Its functional effect is inferred from its position — near, but not within, the alternative exon 3 promoter element — and from the convergence of multiple independent behavioral and neuroimaging phenotypes that it predicts.

The Evidence

Hippocampal volume in cannabis users. The most striking finding for rs2023239 comes from a structural MRI study by Schacht, Hutchison, and Filbey (2012)44 Schacht, Hutchison, and Filbey (2012)
Schacht JP et al. Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users. Neuropsychopharmacology, 2012. The study compared 37 heavy daily cannabis users (average 6+ days/week) with 37 age- and sex-matched healthy controls, plus an expanded group of 94 total cannabis users. After controlling for intracranial volume, tobacco use, age, gender, and education, cannabis users overall showed significantly smaller bilateral hippocampi (left: 6.9% reduction, p=0.002; right: 7.1% reduction, p=0.001) and smaller left amygdalae (p=0.01) compared to controls.

When genotype was incorporated, the rs2023239 C allele emerged as a powerful moderator: C allele carriers showed substantially smaller bilateral hippocampal volumes among cannabis users compared to non-user controls (both p<0.001, Cohen's d=1.48–1.63 — large effects). This gene-by-cannabis interaction was not explained by overall group differences; it was specific to the C allele genotype group within cannabis users. This finding is consistent with the hippocampus being the brain region most densely expressing the CB1 receptor variant isoform associated with this intronic promoter region.

This hippocampal finding is from a single case-control study (n=74 matched pairs) and has not yet been independently replicated in a separate cohort. The effect sizes are large enough to be meaningful, but independent replication is needed before treating this as established rather than emerging.

Cannabis withdrawal and craving. A 5-day abstinence paradigm study by Haughey et al. (2008)55 Haughey et al. (2008)
Haughey HM et al. Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. Addiction, 2008 enrolled 105 daily college-age cannabis users who abstained for 5 days while undergoing repeated assessment of withdrawal symptoms and craving. The rs2023239 T/C genotype showed a significant abstinence-by-genotype interaction on withdrawal severity (F=6.71, p=0.012): T/C carriers experienced substantially greater post-abstinence withdrawal than T/T homozygotes. T/C carriers also showed a main effect of elevated craving across all measurement timepoints (F=4.3, p=0.041), indicating the C allele's effect on craving is not specific to the abstinence period but reflects a baseline difference in reward circuit sensitivity.

Cannabis cue-elicited brain activation. A neuroimaging study by Hutchison et al. (2010)66 Hutchison et al. (2010)
Hutchison KE et al. Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues. Neuropsychopharmacology, 2010 found that rs2023239 C/G allele carriers showed significantly greater activation in the orbitofrontal cortex, inferior frontal gyrus, and anterior cingulate gyrus compared to T/T (A/A) carriers when viewing cannabis-associated cues. These are the brain regions encoding cue salience, habitual behavior, and craving — their heightened reactivity in C allele carriers is consistent with both the withdrawal and craving findings above and with the hippocampal volume data.

Nicotine dependence haplotype. Rs2023239 participates in a CNR1 haplotype with established nicotine dependence associations. In two independent samples (VAND: 688 subjects; VAANX: 961 subjects), Chen et al. (2008)77 Chen et al. (2008)
Chen X et al. Cannabinoid receptor 1 gene association with nicotine dependence. Arch Gen Psychiatry, 2008 identified the haplotype rs2023239–rs12720071–rs806368(C) as significantly associated with nicotine dependence diagnosis and Fagerström Test for Nicotine Dependence scores (p<0.001 in VAND, p=0.009 in VAANX). These associations were female-specific across both samples — male participants did not show the same haplotype signal. This sex-specificity may reflect estrogen–endocannabinoid interactions that modulate nicotine reward differently between sexes.

Nicotine reinforcement paradox. A 2021 laboratory study by Forget et al. (2021)88 Forget et al. (2021)
Forget B et al. The CB1R rs2023239 receptor gene variant significantly affects the reinforcing effects of nicotine, but not cue reactivity, in human smokers. Neuropsychopharmacology, 2021 found a counterintuitive result: C allele carriers (n=39) showed significantly lower nicotine reinforcement — measured by behavioral preference for nicotine-containing cigarettes over denicotinized ones — compared to T/T carriers (n=65). No genotype difference was found for nicotine cue reactivity. This is not necessarily contradictory to the haplotype dependence finding: the reinforcement experiment measures acute nicotine reward in a controlled laboratory context, while dependence develops through different repeated-exposure mechanisms. The C allele may reduce initial acute nicotine reward while still contributing (through haplotype context) to the compulsive continuation patterns that define dependence.

Alcohol cue craving and dependence. A meta-analysis of CNR1 polymorphisms in alcohol dependence (Gamaieddin et al. 202199 Gamaieddin et al. 2021
Gamaieddin I et al. Associations of CB1 cannabinoid receptor (CNR1) gene polymorphisms with risk for alcohol dependence. Drug Alcohol Depend, 2021) found that C allele carriers of rs2023239 showed elevated craving in response to alcohol-associated cues, and a codominant model showed OR 1.33 (95% CI 1.13–1.56) for alcohol dependence risk across pooled samples — though this finding was underpowered (78.7% power at OR=1.5) and the aggregate sample was only 704 cases and 681 controls.

Practical Implications

The convergence of findings across hippocampal volume, withdrawal, craving, and cue reactivity gives rs2023239 a coherent behavioral profile: the C allele is associated with a more reactive endocannabinoid circuit that responds more intensely to cannabis exposure and abstinence. This has clear implications for cannabis use decisions.

The hippocampal volume finding is the most striking: the hippocampus is the brain's primary memory consolidation and spatial navigation hub, and it contains some of the highest CB1 receptor density in the brain. Volume loss in this region with heavy cannabis use — moderated by rs2023239 genotype — is associated with impaired episodic memory, mood regulation, and contextual fear extinction. For C allele carriers, the dose-response relationship between cannabis exposure and hippocampal structure appears steeper.

The sex-specific nicotine finding is also practically relevant for female C allele carriers who smoke: the nicotine dependence haplotype involving rs2023239 suggests a genotype-specific vulnerability that is not apparent in males.

The distinction between rs2023239 and the rs806368-rs1049353 haplotype is important: these variants tag different LD blocks and different functional elements in CNR1, meaning their effects are at least partially independent. Carriers of risk alleles at all three loci face compounding endocannabinoid system vulnerability rather than redundant signals.

Interactions

Rs2023239 is in a separate LD block from rs806368 and rs1049353, which form the primary 3'UTR haplotype block in CNR1. In European populations, rs2023239 tags a second CNR1 haploblock with rs1535255 and rs6454674. The Chen 2008 nicotine study explicitly showed that the nicotine dependence signal involves a three-marker haplotype spanning both LD blocks (rs2023239–rs12720071–rs806368). A three-year longitudinal study of first-episode psychosis by Bobes et al. 2015 found a triple interaction between rs1049353, rs1535255, and rs2023239 predicting positive symptom trajectory — suggesting these variants collectively modulate CNR1 expression regulation in ways relevant to psychosis vulnerability in the context of cannabis use.

FAAH rs324420 — which controls anandamide breakdown and has been co-studied with rs2023239 in both the cannabis cue and withdrawal paradigms — adds a complementary layer: carriers of the FAAH rs324420 C allele (reduced FAAH activity → elevated anandamide) and the CNR1 rs2023239 C allele may face simultaneous upregulation of endocannabinoid tone through two distinct nodes of the same pathway.

Genotype Interpretations

What each possible genotype means for this variant.

TT Normal

Common genotype; standard CB1 receptor expression at this locus

You carry two copies of the T allele at rs2023239, the most common genotype globally (about 62% of people). On the coding strand of CNR1, this corresponds to the A/A genotype described in older literature. The T/T genotype is not associated with the heightened hippocampal volume vulnerability, withdrawal intensity, or craving reactivity that C allele carriers show in cannabis studies. Your CB1 alternative transcript isoform balance at this locus does not appear to confer elevated risk at this specific CNR1 regulatory position, though other CNR1 variants (rs806368, rs1049353) and lifestyle factors remain independently relevant.

CT Intermediate

One C allele — moderately elevated cannabis brain vulnerability and craving reactivity

Heterozygous carriers of the CNR1 rs2023239 C allele were grouped with CC homozygotes in several studies due to the low frequency of CC homozygotes. The Haughey 2008 withdrawal/craving study (n=105 daily users) found T/C carriers — not just C/C — showed significantly greater abstinence-induced withdrawal and overall craving elevation. The Schacht 2012 hippocampal MRI study similarly found that "G allele carriers" (i.e., those with at least one C on the plus strand) showed the hippocampal volume interaction with cannabis use. This means T/C heterozygotes experience most of the genotype effect, not just those with two C copies.

The female-specific nicotine dependence haplotype involving rs2023239 is also relevant for TC women who smoke: the Chen 2008 finding of female-specific nicotine dependence association with the rs2023239–rs12720071–rs806368 haplotype suggests that estrogen may amplify the endocannabinoid-nicotine interaction in a sex-specific way.

The hippocampal finding is based on a single study (n=37 matched pairs) and effect sizes were large (d=1.48–1.63), which, while striking, warrants interpretation with the caveat that independent replication has not been published as of 2026.

CC High Risk

Two C alleles — highest risk at this locus for cannabis brain vulnerability and craving

Because CC homozygotes are rare (approximately 4% globally), most studies group CC and TC carriers together for statistical power. The effect sizes observed for the combined group (e.g., hippocampal volume d=1.48–1.63 in Schacht 2012; elevated withdrawal p=0.012 and craving p=0.041 in Haughey 2008) apply to CC carriers and, on an additive-dosage model, would be at least as pronounced in CC as in TC.

The hippocampal finding is particularly relevant: the hippocampus has among the highest CB1 receptor density in the brain, and it is central to episodic memory formation, contextual learning, and spatial navigation. Progressive hippocampal volume loss — as suggested by the gene-by-cannabis interaction — is associated with impaired short-term memory consolidation, difficulty with context-dependent fear extinction (relevant to anxiety and PTSD vulnerability), and disrupted regulation of HPA axis stress responses.

As a CC homozygote, if you have also inherited risk alleles at rs806368 (TT) and rs1049353 (CT or TT), your CNR1 genetic profile across two separate LD blocks would compound rather than replace the risks documented at individual loci.

The Forget 2021 paradoxical finding (C allele carriers showed lower acute nicotine reinforcement in a laboratory context) is worth knowing: it suggests that CC carriers may not experience strong initial nicotine reward from smoking, yet the female-specific haplotype data show that dependence can still develop through non-reinforcement pathways (e.g., stress relief, habit formation). Low initial reward does not eliminate dependence vulnerability.